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MicroRNAs (miRNAs) are small noncoding RNA mole-
cules that negatively regulate gene expression via deg-
radation or translational repression of their target mes-
senger RNAs (mRNAs). Recent studies have clearly 
demonstrated that miRNAs play critical roles in several 
biologic processes, including cell cycle, differentiation, 
cell development, cell growth, and apoptosis and that 
miRNAs are highly expressed in regulatory T (Treg) 
cells and a wide range of miRNAs are involved in the 
regulation of immunity and in the prevention of auto-
immunity. It has been increasingly reported that miRNAs 
are associated with various human diseases like auto-
immune disease, skin disease, neurological disease and 
psychiatric disease. Recently, the identification of mi-
RNAs in skin has added a new dimension in the regu-
latory network and attracted significant interest in this 
novel layer of gene regulation. Although miRNA re-
search in the field of dermatology is still relatively new, 
miRNAs have been the subject of much dermatological 
interest in skin morphogenesis and in regulating an-
giogenesis. In addition, miRNAs are moving rapidly onto cen-
ter stage as key regulators of neuronal development and 
function in addition to important contributions to neuro-
degenerative disorder. Moreover, there is now compelling 
evidence that dysregulation of miRNA networks is implicated 
in the development and onset of human neruodegenerative 
diseases, such as Alzheimer’s disease, Parkinson's disease, 
Huntington’s disease, Tourette’s syndrome, Down syndrome, 
depression and schizophrenia. In this review, I briefly summa-
rize the current studies about the roles of miRNAs in various 
autoimmune diseases, skin diseases, psychoneurological dis-
orders and mental stress.
[Immune Network 2011;11(5):227-244]
INTRODUCTION
T h e  g r e a t  d i s c o v e r y  o f  m i c r o R N A s  ( m i R N A s )  h a s  r e v o l u -
tionized  current  cell  biology  and  medical  science  (1,2). 
miRNAs  represent  a  large  family  of  endogenous  noncoding 
R N A s  t h a t  c o m p r i s e  a  f u n d a m e n t a l  l a y e r  o f  p o s t - t r a n s c r i p -
tional regulation of gene expression (3,4). miRNAs are found 
in  almost  all  species:  virus,  plants,  nematodes,  fly,  fish, 
mouse, human, and are implicated in a wide array of cellular 
and developmental process (5). It has recently been shown 
that  the  main  function  of  miRNAs  in  mammalian  system  is 
to decrease target messenger RNA (mRNA) levels (6). Recent 
evidence  also  suggests  that  the  number  of  unique  miRNA 
genes in human exceed 1,000, and may be as high as 20,000 
and  it  is  estimated  that  20∼30%  of  all  human  mRNA  are 
miRNA targets (7). More recently, miRNA are also proving to 
be  an  important  link  between  the  innate  and  adaptive  im-
mune systems, and their dysregulation might have a role in 
the  pathogenesis  of  various  diseases  (3,8,9).
    miRNAs constitute a class of small endogenous noncoding 
RNAs of 19∼23 nucleotides that negatively regulate gene ex-
pression  (4,10).  They  are  an  abundant  class  of  gene  regu-
latory molecules in multicellular organisms and modulate the 
expression of many protein-coding genes (4,11,12). They are 
transcribed as a huge double-stranded primary transcript (pri- 
miR) by RNA polymerase II. Subsequently, nuclear enzyme 
Drosha (also known as ribonuclease III) and Pasha convert 
this  precursor  into  a  double-stranded  miRNA  precursor  of MicroRNAs in Autoimmune and Psychoneurological Diseases
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∼70 nulcleotide (pre-miR), which is next transported into the 
cytoplasm by a mechanisms involving the protein Exportin 5 
(3,4,9,13). Finally, Dicer enzyme processes this precursor into 
the  22-nucleotide  double-stranded  miRNA.  This  duplex  is 
then unwinded, and the leading strand (“guide strand”), one 
of the two strands, is incorporated into the RNA-induced si-
lencing  complex  (RISC),  which  is  comprise  Agonaute  and 
other proteins (3,13,14). miRNAs incorporated in the RISC are 
able  to  bind  to  the  3'  untranslated  region  (UTR)  of  target 
mRNAs causing a block of translation or mRNA degradation 
depending on the level of complementarity (4,11). The other 
strand  so-called  “passenger  strand”  is  degraded  (3,4,15). 
Recent  studies  have  clearly  demonstrated  that  miRNAs  play 
critical roles in several biologic processes, including cell dif-
ferentiation, cell development, cell growth, and apoptosis by 
regulating  gene  expression  through  either  the  inhibition  of 
mRNA translation or the induction of its degradation (9,16,17). 
The analysis of human neoplasias of different tissue origins 
has  shown  deregulated  miRNA  expression  (18-20).  miRNA 
expression can be induced or expressed by a variety of stim-
uli  and  mechanisms.  These  stimuli  include  direct  transcrip-
tional activation or repression from transcriptional enhancers, 
epigenetic modifications of the genome, genomic amplifica-
tion  or  deletion,  cellular  stress  and  inflammatory  stimuli 
(6,8,16,20). The effect of inducing or repressing miRNA ex-
pression  can  influence  most  biological  processes,  such  as 
apoptosis,  cell fate  specification,  cell proliferation,  DNA re-
pair,  cell  cycle,  and  DNA  methylation  (17,20,21).
    As mentioned above, miRNAs also have an essential role 
in  both  the  innate  and  adaptive  immune  system.  Proper 
miRNA expression is required for correct differentiation of im-
mune cells (22). Immune responses are symphonies of mo-
lecular  and  cellular  interactions,  with  each  player  doing  its 
part to produce the composite behavior we see as effective 
host defense, or when discoordinated, as immunopatholgy or 
immunodeficiency  (23). 
    Lu et al. performed a comprehensive analysis to the human 
miRNA disease association data, which is manually collected 
from publication (24). Furthermore, importantly, it has been 
increasingly reported that miRNAs are associated with various 
human diseases like autoimmune diseases (25-30), skin dis-
eases  (15,31-33),  neurological  diseases  (34,35),  psychiatric 
diseases (36-38), cancer (3,17,39-43), cardiovascular diseases 
(44-47),  asthma  (48-50)  and  microbial  infection  (8,51-55).
    Recent studies have revealed links between miRNA func-
tion and autoimmunity and have also showed the importance 
of miRNA regulation in safeguarding Treg cell function in the 
prevention of autoimmunity (9,56-60). Cobb et al. reported 
that regulatory T (Treg) cells have a miRNA expression profile 
distinct from conventional CD4
＋ T cells (58). Moreover, Zhou 
et al. developed mice with conditional Dicer knockout within 
the Treg cells lineage and used these mice to monitor Treg 
cell development and function in the absence of functional 
miRNA (57). They reported that although thymic Treg cells 
developed normally in these miRNA-deficient mice, the cells 
exhibited altered differentiation and dysregulaltion in the pe-
riphery (57). Specifically, the Dicer-deficient Treg cells failed 
to remain stable and altered expression of multiple genes and 
proteins,  including  neuropilin  1,  glucocorticoid-induced  tu-
mor necrosis factor receptor, and cytotoxic T lymphocytes an-
tigen  4  (CTLA-4)  associated  with  the  Treg  cells  fingerprint, 
including  Foxp3  (9,56-58).  In  addition  to  their  instability, 
Dicer-deficient Treg cells lost suppressor activity in vivo, and 
the  mice  rapidly  developed  fatal  systemic  autoimmune  dis-
ease resembling the Foxp3 KO phenotype (57). Interestingly, 
Liston  et  al.  reported  that  in  disease-free  Foxp3
Cre/wtDicer
fl/fl 
mice, Dicer-deficient Treg cells retained some suppressive ac-
tivity,  albeit  reduced  compared  to  wild-  type  mice  (56). 
However,  in  diseased  Foxp
CreDicer
fl/fl  mice  exhibiting  in-
flammatory conditions, Dicer-deficient Treg cells were com-
pletely devoid of any suppressor activity (56). Depletion of 
miRNA within Treg cell lineage resulted in fatal autoimmune 
syndrome indistinguishable from that observed in Foxp3 mu-
tant mice devoid of Treg cells (56). These data suggest that 
miRNAs preserve stable Treg cell function under inflammatory 
conditions and that Treg cells are indispensable for prevent-
ing autoimmunity. Moreover, recently, numerous studies pro-
vide evidence that Treg cells play important roles in human 
autoimmune diseases (9,31,59,61). It is becoming increasingly 
clear from cell culture and animal studies that proper miRNA 
regulation is critical for the prevention of autoimmunity and 
normal immune function. However, it is not yet well under-
stood whether miRNA dysregulation could play a role in auto-
immune disease pathogenesis in human patients. Several re-
cent studies have uncovered possible roles for miRNAs regu-
lation in autoimmune disease, specifically rheumatoid arthritis 
(RA), systemic lupus erythematosus (SLE), multiple sclerosis 
(MS),  asthma,  inflammatory  bowel  disease  (IBD)  including 
Crohn’s disease (CD) and ulcerative colitis (UC), autoimmune 
diabetes  and  psoriasis  (9,21,60,61).
    Recently, the identification of miRNAs in skin has added a 
new  dimension  in  the  regulatory  network  and  attracted  sig-MicroRNAs in Autoimmune and Psychoneurological Diseases
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nificant interest in this novel layer of gene regulation (32,62,63). 
Although miRNA research in the field of dermatology is still 
relatively new, miRNAs have been the subject of much der-
matological interest. miRNAs play a key role in skin morpho-
genesis  and  in  regulating  angiogenesis  (62).
    Aging-related neurodegenerative diseases are the culmina-
tion of many different genetic and environmental influences. 
Recent  evidence  suggests  that  miRNAs  may  be  contributing 
factor in neurodegeneration (64). Although discovered in the 
framework  of  worm  development,  miRNA  are  now  appre-
ciated to play a dynamic role in many mammalian brain-re-
lated  biochemical  pathway,  including  neuroplasticity  and 
stress responses (64). Research about miRNA in the context 
of  neurodegeneration  is  accumulating  rapidly  (36,37,65-70). 
Psychiatric illnesses are disabling disorders with poorly under-
stood underlying pathophysiologies (66). Interestingly, there 
is now compelling evidence that dysregulation of miRNA net-
works is implicated in the development and onset of human 
neruodegenerative  diseases,  such  as  Alzheimer’s  disease 
(AD), Parkinson’s disease (PD), Huntington’s disease (HD), 
Tourette’s syndrome, Down syndrome (DS), depression and 
schizophrenia (36,38,67-74). In this review, I briefly summa-
r i z e  t h e  c u r r e n t  k n o w l e d g e  o f  r o l e s  o f  m i R N A s  i n  a u t o -
immune  diseases,  skin  disease,  and  psychiatric  and  neuro-
logical  disorders.
miRNAs IN RHEUMATOID ARTHRITIS (RA) 
RA is a common chronic inflammatory disease characterized 
by raidographic joint destruction with severe functional dete-
rioration and high mortality (9,75). A hallmark pathological 
feature of RA is the infiltration and accumulation of T cells 
in the synovium of joint (9,75). As discussed, dysregulation 
of miRNAs has been shown to be a hallmark of cancer and 
now investigators are examining their role in the pathogenesis 
of  inflammatory  diseases.  Abnormal  expression  of  miRNAs 
has also been found in patients with RA (26). Interestingly, 
miR-146 and miR-155 have been a particular focus for inves-
tigators, and these two miRNAs have been shown to be in-
duced by proinflammatory stimuli such as Toll-like receptors 
(TLRs), IL-1 and, TNF-α (76-79). They have also been de-
tected in synovial fibroblasts and rheumatoid synovial tissue 
(76). Both have multiple targets, with miR-146 inhibiting TLR 
signalling and miR-155 regulating Th1 cells and also, interest-
ingly,  positively  regulating  mRNA  for  TNF-α (76).
    Stanczyk et al. provided the first description of increased 
expression of miR-146 and miR-155 in RA synovial fibroblasts 
compared  with  osteoarthritis  synovial  fibroblasts  (79).  Fur-
thermore,  compared  with  monocytes  from  RA  peripheral 
blood,  RA  synovial  fluid  monocytes  displayed  higher  levels 
of miR-155 (79). Additionally, transfection of miR-155 in RA 
synovial fibroblasts revealed matrix metalloproteinase 3 as a 
potential  target  of  miR-155,  suggesting  that  miR-155  might 
modulate downstream tissue damage (79). Recently, Nakasa 
et al. showed that miR-146 was highly expressed in RA syno-
vial tissue compared with osteoarthritis and normal synovial 
tissue (78). In situ hybridization studies revealed that miR-146 
expression could be detected in RA synovial tissue primarily 
in CD68
＋ macrophages, but also in some CD3
＋ T cell subsets 
and CD79a
＋ B cells (78). Pauley et al. demonstrated differ-
ential expression of miRNA in peripheral blood mononuclear 
cells (PBMCs) of RA, with between 1.8-fold and 2.6-fold in-
crease in miR-16, miR-132, miR-146 and miR-155 expression, 
whereas miRNA let-7a expression was not significantly differ-
ent,  as  compared  with  healthy  control  individuals  (77). 
Interestingly, increased miR-16 and miR-146 expression corre-
lated with active disease in RA patients. However, there was 
no correlation between the observed increase in miRNA ex-
pression and the patients’ age, race, or medications (77). In 
addition, two targets of miR-146a, namely TNF receptor- asso-
ciated  factor  6  (TRAF6)  and  IL-1  receptor-associated  kinase 
1 (IRAK-1), were similarly expressed between RA patients and 
control individuals, despite increased expression of miR-146a 
in  patients  with  RA  (77).  In  vitro  studies  revealed  that  re-
pression of TRAF6 and/or IRAK1 in THP-1 human monocytes 
resulted in up to an 86% reduction in TNF-α production, im-
plicating that normal miR-146a function could be critical for 
the  regulation  of  TNF-α production  (77).  Given  that  pro-
longed  TNF-α production  is  known  to  play  a  role  in  RA 
pathogenesis, these data suggest a possible mechanisms con-
tributing to RA pathogenesis, where miR-146 is up-regulated 
but  unable  to  properly  regulate  TRAF-6/IRAK  1,  leading  to 
prolonged  TNF-α production  in  RA  patients  (77). 
  Recently, Luo et al. reported that miRNAs are key players 
in rheumatic diseases by regulating major pathogenic mole-
cules, such as TNF, central signal pathways, such as type 1 
IFN  pathway  and  critical  immunuoregulatory  cells,  such  as 
Treg cells (80). They also reported that in animals, blockade 
of miRNA maturation by the deletion of Dicer or Drosha, in-
terference  with  miRNA  function  by  the  mutation  of  Roquin 
and  the  altered  expression  of  individual  miRNA  (miR-146a) 
or miRNA cluster (miR-17-92) all lead to the development of MicroRNAs in Autoimmune and Psychoneurological Diseases
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autoimmune disease (80). Growing evidence also reveals the 
differential expression of certain immunity-regulating miRNA 
in  rheumatoid  patients  (26,80).  However,  RA  is  an  auto-
i m m u n e  p a t h o l o g y  t h e  e t i o l o g y  o f  w h i c h  i s  s t i l l  o b s c u r e .  
Although  a  multifactorial  pathogenesis  has  been  hypothe-
sized, the precise mechanisms leading to the disease are still 
poorly  understood  at  the  molecular  level  (26).  Recently, 
miRNA expression profile analysis highlighted that miR-223 is 
the only miRNA that is strikingly deregulated in peripheral T 
c el ls fr om  RA  p at ie nt s c om pa re d w it h h ea lt hy  do n or s (3 0). 
Further analysis by quantitative reverse transcription-polymer-
ase chain analysis confirmed that miR-223 is over-expressed 
i n  T  c e l l s  f r o m  R A  p a t i e n t s  c o m p a r e d  w i t h  h e a l t h y  d o n o r s  
(30).  Moreover,  purification  of  different  T  cell  population 
from RA patients highlights that miR-223 is expressed at high-
er levels in naive CD4
＋ cells, whereas its expression is barely 
detectable in Th-17 cells (30). A deeper analysis of the bio-
logic  functions  and  effects  of  the  expression  of  miR-223  in 
T cells is needed to clarify the exact link between these find-
ings and the disease. More recently, Li et al. investigated the 
expression pattern and function of miRNA in CD4
＋ T cells 
from patients with RA (75). miRNA expression profile analysis 
revealed that miR-146a expression was significantly up-regu-
lated  while  miR-363  and  miR-498  were  down-regulated  in 
CD4
＋ T cells of RA patients (75). Interestingly, the level of 
miR-146a expression  was  positively  correlated  with level of 
TNF-α,  and  in  vitro s t u d i e s  s h o w e d  T N F - α  u p - r e g u l a t e d  
miR-146a  expression  in  T  cells  (75).  Moreover,  miR-146a 
over-expression  was  found  to  b e  s u p p r e s s  J u r k a t  T  c e l l  
apoptosis.  Additionally,  transcriptome  analysis  of  miR-146a 
over-expression  in  T  cells  identified  Fas  associated  factor  1 
(FAF1) as miR-146a-regulated gene, which was critically in-
volved  in  modulating  T  cell  apoptosis  (75).  These  findings 
that miR-146a over-expression suppresses T cell apoptosis in-
dicate a role of miR-146a in RA pathogenesis and provide po-
tential  novel  therapeutic  targets.
miRNAs IN SYSTEMIC LUPUS ERYTHEMATOSUS 
(SLE)
SLE is a systemic inflammatory autoimmune disease charac-
terized by the presence of autoantibodies against numerous 
self-antigens  including  chromatin,  ribonucleoproteins,  and 
phospholipids (59,81). Clinical manifestations of SLE are di-
verse and include malar rash, photosensitivity, arthritis, glo-
merulonephritis, and neurological disorders (59,81,82). SLE is 
also characterized by loss of tolerance to self-antigens and ac-
tivation of autoreactive T cells and Treg cells play a critical 
role  in  controlling  the  activation  of  autoreactive  T  cells 
(9,59,83). Several studies have found numerical and/or func-
tional  insufficiency  of  Treg  cells  in  humans  and  mice  with 
SLE (59,83). Dai et al. reported the findings of their micro-
array expression analysis of  miRNA  in PBMCs  from  23  SLE 
patients and 10 healthy controls (82). In these SLE patients, 
7  miRNAs  (miR-196a,  miR-17-5p,  miR-409-3p,  miR-141, 
miR-383, miR-112, and miR-184) were down-regulated and 9 
miRNAs  (miR-189,  miR-61,  miR-78,  miR-21,  miR-142-3p, 
miR-342, miR-299-3p, miR-198, and miR-298) were up-regu-
lated as compared with healthy controls (82). These data sug-
gest a possible role for miRNA as diagnostic markers and as 
factors  involved  in  the  pathogenesis  of  SLE.  Currently, 
Divekar et al. investigated mechanisms of potential Treg cells 
defects in SLE using lupus-prone MRL-Fas
lpr/lpr (MRL/lpr) and 
congenic Fas-intact MRL-Fas
＋/＋ mice and in non-autoimmune 
C3H/HeOuj mice (83). Surprisingly, they found a significant 
increase in CD4
＋CD25
＋Foxp3
＋ Treg cells in speen, lymph 
nodes,  and  thymus  of  lupus-prone  mice,  albeit  with  an  al-
tered phenotype (CD62L
−CD69
＋) and with a reduced sup-
pressive  capacity,  in  the  lymphoid  organs  of  MRL  strains   
compared  wtih  non-autoimmune  C3H/HeOuj  mice  (83).  In 
addition, the authors found a profund reduction in Dicer ex-
pression and an altered miRNA profile in MRL/lpr Treg cells. 
They also found that the reduced functional capacity of MRL 
T r e g  c e l l s  w a s  a s s o c i a t e d  w i t h  a  charactieristic  phenotype, 
i.e.,  increased  CD69  and  reduced  CD62L  expression  (83). 
Unexpectedly,  despite  having  a  reduced  level  of  Dicer, 
MRL/lpr Treg cells exhibited a significant overexpression of 
several  miRNAs,  including  let-7a,  let-7f,  miR-16,  miR-23, 
miR-23b, miR-27b, miR 27a and miR-155 (83). Moreover, si-
m u lt an eo u s ap pe ara nc e  of  Di ce r i nf su ffi ci en c y a nd  m iR- 1 55 
overexpression  in  diseased  mice  suggests  a  Dicer-indepen-
dent alternative mechanisms of miRNA regulation under in-
flammatory  conditions  (83).  Using  computational  and  ex-
perimental approaches, they further identified miR-155 to reg-
ulate altered phenotype of Treg cells in SLE. Importantly, they 
reported that the progression to autoimmune disease is asso-
ciated  with  increased miR-155  expression  despite a marked 
reduction in Dicer expression in Treg cells from MRL/lpr mice 
(83). These data suggest a role of Dicer and miR-155 in con-
ferring Treg cell defect in SLE. Currently, Mellor and Munn 
also reported that despite critical role of Treg cells in main-
taining periperal toleracne, when Treg cells are isolated from MicroRNAs in Autoimmune and Psychoneurological Diseases
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Figure 2. Changes of miRNA signatures of regulatory T (Treg) cells 
separated from peripheral blood of type 1 diabetic patients (See Text
for details). 
Figure 1. Various miRNAs are involved in diverse metabolic pro-
cesses, diabetes and diabetic complications. A variety of miRNAs are
involved in insulin synthesis, glucose metabolism and lipid meta-
bolism. Dysregulations of diverse metabolic processes lead to dia-
betic complications, such as diabetic cardiopathy and diabetic ne-
phropathy (See Text for details).
noninflammed  lymphoid  tissues  or  blood  of  helathy  in-
dividuals they are functionally quiescent (resting), and must 
be activated to manifest functional suppressive activity (84). 
Conversely,  under  cetain  inflammatory  conditions,  surprig-
ingly,  Treg  cells  may  undergo  rapid  reprogramming  to  ac-
quire helper/effector functions (84). Moreover, Treg cells and 
Foxp3  are heterogenous and Treg cells may promote pathol-
ogy  in  autoimmune  syndromes  by  undergoing  reprogram-
ming or manifesting less potent suppression (84). Taking to-
gether, identifying mechanisms underlying Treg c ell impair-
ment  in  autoimmune  diseases  will  open  new  avenues  of 
modulating  immune  tolerance  and  suppressingdisease  (83).
miRNAs IN DIABETES 
Diabetes is the deadly global health problem. The discovery 
of  miRNA  and  subsequent  reports  illustrating  their  roles  in 
regulating glucose and lipid metabolism have opened up a 
novel mode of fine-tuning genes that control diverse facets 
of metabolic regulation (29). Maintenance of appropriate lev-
e l s  o f  c i r c u l a t o r y  g l u c o s e  l e v e l s  r e s u l t s  f r o m  a  b a l a n c e  b e -
tween normal insulin secretion and action. Dysregulation at 
any  step  of  this fine  tuning  is  responsible  for  the  initiation 
of type  1  diabetes  and  insulin  resistance that culminates in 
type 2 diabetes (28,29). Apart from the various mechanistic 
regulators of insulin secretion and action, miRNAs have also 
emerged as novel regulator of these phenomena and hence 
appropriately referred to as “ribo-regulator of glucose homeo-
stasis” (85). Along these lines, a major player that emerged 
as a significant mediator of insulin release and thereby of glu-
cose homeostasis is the pancreatic islet specific miR-375 (29). 
It is one of the earliest miRNAs to be identified as possessing 
a validated functional role in the pancreas where it negatively 
regulates glucose-stimulated insulin release in a calcium in-
dependent  manner  (29).  The  authors  found  that  over-ex-
pression of miR-375 led to significant reduced levels of Vtila 
protein (t-SNAREs yeast homologue 1A that is critical in in-
sulin  vesicle  biogenesis  and  recycling)  and  the  myotrophin 
(29). Quite interestingly, miR-375 was identified as the most 
abundant intra-islet miRNA (29). miR-375 appears to be the 
most well studied as far as the regulation of insulin release 
and  glucose  homeostasis  is  concerned.  Very  recent  studies 
found  61  glucose  regulated  miRNAs  from  a  total  of  108 
miRNAs  in  the  mouse  insulinoma  cell  line,  MIN6  (29).  Of 
these,  most  of  the  miRNAs  up-regulated  and  only  few  that 
included miR-296, miR-184 and miR-160 were down-regulated MicroRNAs in Autoimmune and Psychoneurological Diseases
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(29). Pandey et al. summarized features of the known roles 
of miRNAs in cellular functions (29). As shown in Fig. 1, the 
authors reported that various miRNAs have been identified to 
b e  c r i t i c a l  i n  d i v e r s e  m e t a b o l i c  p r o c e s s ,  d y s r e g u l a t i o n  o f  
w h i c h  l e a d  t o  d i a b e t e s  a n d  i t s  c o m p l i c a t i o n s  ( 2 9 ) :  m i R N A s  
involved  in  insulin  synthesis  are  miR-9,  miR-34a/146,  miR- 
375, miR-124a, and miR-30d. miRNAs involved in glucose me-
tabolism are miR-29a and miR-145. miRNAs involved in lipid 
metabolism are miR-14, mir-122, miR-143, miR-103/1l07 and 
miR-278 (29). As for diabetic complications, miRNAs involved 
in diabetic cardiomyopathy are miR-133, miR-1 and miR-320, 
and  miRNAs  involved  in  diabetic  nephropathy  are  miR-192 
and  miR-377  (29).
  As aformentioned, Treg cells are critical regulators of auto-
i m m u n e  d i s e a s e s ,  i n c l u d i n g  t y p e  1  D M  ( 9 , 3 1 , 5 9 ) .  I t  i s  h y -
p o t h e s i z e d  t h a t  T r e g  c e l l  f u n c t i o n  c a n  b e  i n f l u e n c e d  b y  
changes  in  the  expression  of  specific  miRNAs.  Recently, 
Hezova et al. performed miRNA profiling in a population of 
Treg cells separated from peripheral blood of five type 1 dia-
betic patients and six healthy donors (86). In Treg cells of 
diabetic patients they found significantly increase expression 
of  miR-510  and  decreased  expression  of  both  miR-342  and 
miR-191, as shown in Fig. 2 (86). When comparing Treg cells 
and  conventional  T  cells, they revealed  that  Treg cells  had 
significant  higher  expression  of  miR-146a  and  lower  ex-
pression of eight specific miRNAs (miR-20b, miR-31, miR-99a, 
miR-100,  miR-125b,  miR-151,  miR-335,  and  miR-365).  This 
may be the first study demonstrating changes in miRNA ex-
pression profiles occurring in Treg cells of type 1 DM patients 
a n d  a  m i R N A s  s i g n a t u r e  o f  a d u l t  T r e g  c e l l s  ( 8 6 ) .
    DM impairs endothelial cell (EC) function and postischemic 
reparative  neovascularization by  molecular  mechanisms  that 
are not fully understood. A recent study showed that miR-503 
expression in ECs is up-regulated in culture conditions mim-
icking DM (high D-glucose) and ischemia-associated starva-
tion (low growth factors) and that miR-503 expression is in-
creased  in  ischemic  limb  muscles  of  streptozotocin-diabetic 
mice and in ECs enriched from these muscles (25). The au-
thors also investigated miR-503 and target gene expression in   
muscular specimens from the amputated ischemic legs of dia-
betic patients. In addition, they found that in diabetic mus-
cles,  miR-503  expression  was  remarkably  higher  and  it  in-
versely  correlated  with  cdc25  protein  expression,  and  that 
plasma miR-503 levels were also elevated in the diabetic in-
dividuals (25). These data suggest miR-503 as a possible ther-
apeutic target in diabetic patients with critical limb ischemia. 
miRNAs IN MULTIPLE SCLEROSIS (MS)
As a prototype of organ-specific autoimmune disease, MS is 
manifested by chronic inflammatory demyelination of the cen-
tral nervous system (CNS) and is one of the foremost cause 
of nontraumatic neurological disability in young adults (87). 
The disease is clinically heterogenous, with abut 80% of pa-
tients  developing  the  relapsing-remitting  multiple  sclerosis 
(RRMS) subtype (21,87,88). Because of limited understanding 
of the pathogenesis of MS and a lack of sensitive biomarkers, 
according to the present criteria, the diagnosis of MS still de-
pends on repeated occurrence of the disease (87). In addi-
tion,  the  signs  and  symptoms  of  MS  usually  share  consid-
erable  similarity  with  those  of  other  CNS  inflammatory  dis-
eases, such as neuromyelitis optica and this leads to consid-
erable therapeutic and diagnostic difficulties (88). However, 
CD4
＋ T cell-mediated autoimmunity has long been accepted 
as one of the most important aspects of MS pathogenesis, es-
pecially  for  the  early  initiation  disease  (87).  Importantly, 
Keller et al. investigated the expression profiles of 866 human 
miRNAs (87). In detail, they analyzed the miRNA expression 
in blood cells of 20 patients with RRMS and 19 healthy con-
trols using human miRNA microarray and the Geniom Real 
Time  Analyzer  platform.  They  identified  165  miRNAs  that 
were  significantly  up-  or  down-regulated  in  patients  with 
RRMS as compared to healthy controls (87). They also found 
that the best single miRNA marker, hsa-miR-145, allowed dis-
criminating MS  from controls  with  a specificity  of 89.5%,  a 
sensitivity of 90.0%, and an accuracy of 89.7%. Additionally, 
t h ey  fo u nd  t ha t a  se t o f 4 8  mi RN As  th at  w as e v alu at e d b y 
r a d i a l  b a s i s  f u n c t i o n  k e r n e l  s u p p o r t  v e c t o r  m a c h i n e s  a n d  
10-fold cross validation yielded a specificity of 95%, sensitivity 
of  97.6%,  and  an  accuracy  of  96.3%.  While  43  of  the  165 
miRNAs deregulated in patients with MS have previously been 
related to other human disease, the remaining 122 miRNAs 
are exclusively associated with MS (87). These data suggest 
that miRNA expression signature may represent a potentially 
useful biomarker for the diagnosis for MS and that dysregula-
tion of miRNA expression could play a role in the complex 
pathogenesis  of  MS.
    As mentioned, defects in Treg-cell functions have been de-
scribed in MS and a major goal of MS immunotherapy is to 
induce  Treg  cells  in  a  physiological  fashion  (21).  Clinical 
studies in MS patients showed that Treg cell dysfunction oc-
c u r r e d  i n  t h e  i n i t i a l  s t a g e  o f  the  disease  (21).  The  immu-
nosuppressive  drugs  including  glatiramer  acetate  (GA)  now MicroRNAs in Autoimmune and Psychoneurological Diseases
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approved for the clinical treatment of MS work mainly by in-
creasing  the  frequency  of  Treg  cells  or  by  changing  the 
Th1-Th2  bias  (88,89).  GA  is  a  mixture  of  synthetic  poly-
peptides  composed  of  four  amino  acids  resembling  myelin 
basic protein (89). Interestingly, miR-155 deficiency in Treg 
cells results in increased suppressor of cytokine signaling 1 
(SOCS1)  expression  accompanied  by  impaired  activation  of 
signal transducer and activator of transcription 5 (STAT5) tran-
scription factor in response to limiting amount of IL-2 (90). 
Foxp3  dependent  regulation  of  miR-155  maintains  com-
petitive fitness of Treg cell subsets by targeting SOCS 1 (90). 
A recent study by Du et al. (88) identified Th-17 cell-asso-
ciated miR-326, whose expression was highly correlated with 
disease  severity  in  patients  with  MS  and  mice  with  ex-
perimental autoimmune encephalitis (EAE). In vivo silencing 
of miR-326 resulted in fewer Th-17 cells and mild EAE, and 
i t s  o v e r e x p r e s s i o n  l e d  t o  m o r e  T h - 1 7  c e l l s  a n d  s e v e r e  E A E 
(88).  They  also  found  that  miR-326  promoted  Th-17  differ-
entiation  by  targeting  Ets-1,  a  negative  regulator  of  Th-17 
differentiation.  These  results  suggest  a  critical  role  for 
miR-326  in  the  regulation  of  Th-17  differentiation  and  the 
pathogenesis  of  MS.  More  recently,  De  Santis  et  al.  per-
f o r m e d  a  g e n o m e - w i d e  e x p r e s s i o n  a n a l y s i s  o f  h u m a n  m i -
RNAs  in  CD4
＋CD25
high  bona  fide  Treg  cells  obtained  from 
peripheral  blood  of  MS  patients  and  healthy  donors  (27). 
T h e y  f o u n d  2 3  h u m a n  m i R N A s  d i f f e r e n t i a l l y  e x p r e s s e d  b e -
tween CD4
＋CD25
high bona fide Treg cells from MS patients 
vs. healthy donors, but, conversely, among the deregulated 
miRNAs,  members  of  the  miR-106b-25  were  found  down- 
regulated in MS patients when compared to healthy donors 
in CD4
＋CD25
high CD127
dim/− Treg cells (27). Interestingly, the 
ratio  between  Treg/Teff  showed  an  enrichment  of  these 
miRNA  in  Treg  cells  derived  from  patients  if  compared  to 
healthy controls (27). This is the first study that investigates 
miRNA  expression  profile  in  CD4
＋ CD25
high  Treg  cells  iso-
lated from peripheral blood of MS patients. These data sug-
gest that the deregulation of this miRNA cluster may alter Treg 
cell  activity  in  course  of  MS,  by  altering  TGF-β biological 
functions  and  that  the  abnormal  expression  of  miRNAs  in 
Treg cells might play a role in the pathogenesis of MS (27). 
Emerging  evidence  suggest  that  miRNA  dysregulation  may 
contribute to the pathogenesis of MS. In the near future, fur-
ther understanding of the role of miRNAs in intracellular sig-
naling,  the  expression  of  proteins  involved  in  immune  re-
sponse, modulation of cytokines and chemokines, adhesion 
and  costimulatory molecules  and  the interplay between the 
immune system and CNS should help to define the role of 
miRNAs in autoimmunity, and provide an exciting framework 
for  developing  new  biomarkers  and  new  therapeutic  inter-
ventions  in  MS  (21).
miRNAs IN ASTHMA
Asthma is a chronic inflammatory disease of the airway, tissue 
remodeling, and a decline in respiratory function. The clinical 
condition  is  characterized  by  episodic  breathlessness  and 
wheezing,  together  with  enhanced  airway  hyperrespon-
siveness (49). The traditional view that interindividual risk for 
asthma, like other complex disease, is determined solely by 
interactions  between  genetic  polymorphisms  and  environ-
mental  exposures  needs  to  be  reconcile  with  new  findings 
of a large body research, suggesting that epigenetic mecha-
nisms  also  may  contribute  (49).  These  mechanisms  include 
genomic imprinting, histone modification, altered DNA meth-
ylation of regulatory sequences in Th and other genes, and 
r e g u l a t i o n  b y  m i R N A ,  w h i c h  m a y  c h a n g e  a s t h m a  r i s k  a f t e r  
conception  via  environmentally  mediated  epigenetic  dis-
ruption of gene expression (48,91). As discussed, aberrant ex-
pression  of  miRNA  has  been  shown  to  contribute  to  the 
pathogenesis of many human diseases and may serve as val-
uable  diagnostic  or  prognostic  disease  markers  (27,60). 
However, studies relevant to asthma or asthma risk are still 
lacking,  except  for  a  recent  report  demonstrating  that  ＋
3142C/G allele in the HLG mRNA influences miRNA targeting 
of HLA-G and is associated with risk asthma (49). As men-
tioned, Tan et al. identified HLA-G that is a nonclassic, class 
1  HLA  molecule  possessing  important  immunomodulatory 
properties,  as  an  asthma-susceptibility  gene  and  discovered 
the  risk  of  asthma  in  a  child  was  determined  by  both  the 
child’s  HLA-G  genotype  and  the  mother's  affection  status 
(48). They also reported a single nucleotide polymorphisms 
(SNP) in the 3'UTR of HLA-G that influence the targeting of 
three miRNAs to this gene, suggesting that allele-specific tar-
geting  of  these  miRNAs  accounts, a t  l e a s t  i n  p a r t ,  f o r  t h e i r 
earlier observations on HLA-G and the risk of asthma (48). 
These findings suggest that despite many limitations, there is 
a great promise that the study of environmental epigenetics 
will help us understand a theoretically preventable disease.
    Lu et al. identified a miRNA signature in allergic airway in-
flammation, which includes miR-21 that modulated IL-12 (92). 
In  details,  they  identified  21  miRNAs  with  differential  ex-
pression  between  doxycycline-induced  lung-specific  IL-13 MicroRNAs in Autoimmune and Psychoneurological Diseases
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transgenic mice (with allergic airway inflammation) and con-
trol  mice.  In  particular,  they  observed  over-expression  of 
miR-21 and under-expression of miR-1 in the induced IL-13 
transgenic mice compared with control mice (92). Although 
IL-13-induced  miR-21  expression  was  IL-13Rα1  dependent, 
allergen-induced miR-21 expression was mediated mainly in-
dependent of IL-13Rα1 and STAT6 (92). Notably, predictive 
algorithms  identified  potential  direct  miR-21  targets  among 
IL-13-regulated  lung  transcripts,  such  as  IL-12p35  mRNA, 
which was decreased in IL-13 transgenic mice (92). Mutating 
miR-21 binding sites in IL-12p35 3'UTR abrogated miR-21-me-
diated  repression  (92).  Together,  they  have  identified  a 
miRNA  signature  in  allergic  airway  inflammation,  which  in-
cludes miR-21 that modulates IL-12, a molecule germane to 
Th  cell  polarization  (92).
  As discussed, allergic asthma is an inflammatory disease of 
the  lung  characterized  by  abnormal  Th-2  lymphocyte  re-
sponse to inhaled antigens (92). The molecular mechanisms 
leading to the generation of Th-2 response remain unclear. 
Recently, Mattes et al. showed that in vivo activation of TLR4 
by house dust mite antigens leads to the induction of allergic 
disease,  a  process  that  is  associated  with  expression  of  a 
unique  subset  of  miRNAs (49).  They also  reported  that  se-
lective blockade of miR-126 suppressed the asthmatic pheno-
type,  resulting  in  diminished  Th-2  responses,  inflammation, 
airways  hyperresponsiveness,  eosinophil  recruitment,  and 
mucus  hypersecretion  (49).  In  addition,  they  observed  that 
miR-126 blockade resulted in augmented expression of POU 
domain class 2 associating factor 1, which activated the tran-
scription  factor  (TF)  PU.1  that  alters  Th-2  cell  function  via 
negative regulation of GATA3 expression (49). These findings 
suggest that targeting miRNA in the airways may lead to an-
ti-inflammatory  treatment  of  allergic  asthma.
    Evidence increasingly assigns an immunosuppressive role 
for miRNA in immunity, but relatively few miRNAs have been 
studies,  and  an  overall  understanding  of  the  importance  of 
these  regulatory  transcripts  in  complex  in  vivo s y s t e m s  i s  
lacking.  Recently,  Polikepahad  et  al.  performed  the  global 
analysis  of  miRNA  expression  and  function  in  allergic  lung 
disease, an experimental model of asthma, employing multi-
ple technologies (50). Deep sequencing and microarray anal-
yses of the mouse lung short RNAome revealed numerous ex-
tant  and  novel  miRNA  and  other  transcript  classes  (50).   
Interestingly,  similar  to  mRNAs,  lung  miRNA  expression 
changed dynamically during the transition from the naive to 
the  allergic  state,  suggesting  numerous  functional  relation-
ships (50). A possible role for miRNA editing in altering the 
lung  mRNA  target  repertoire  was  also  identified.  Multiple 
members  of  the  highly  conserved  let-7  miRNA  family  were 
the most abundant lung miRNAs, and they confirmed in vitro 
that IL-13, a cytokine essential for expression for allergic lung 
disease, is regulated by mmu-let-7a (50). These findings re-
vealed unexpected complexity  in miRNAome underlying al-
lergic lung disease and demonstrated that a proinflammatory 
role  of  let-7  miRNAs  (50).
miRNAs IN PSORIASIS
Psoriasis  is  a  skin  disorder  that  is  characterized  by  eryth-
ematous scaling plaques, which are the result of inflammatory 
infiltrates. Psoriasis is thought to be a T cell-mediated disease 
of autoimmune origin, based on histological findings, mouse   
models,  and  the  therapeutic  efficacy  of  TNF-targeted  thera-
pies (31). Psoriasis is the most prevalent chronic inflammatory 
skin disease in adults, with a substantial negative impact on 
the  patient’s  quality  of  life.  Interestingly,  Sonkoly  et  al. 
showed that psoriasis-affected skin has a specific miRNA ex-
pression profile when compared with healthy human skin or 
with another chronic inflammatory skin disease, atopic ecze-
ma (93). Among the psoriasis specific miRNAs, the authors 
identified  leukocyte-derived  miRNAs  and  one  keratino-
cyte-derived miRNA, miR-203 (93). In a panel of 21 different 
human organs and tissues, miR-203 showed a highly skin-spe-
cific expression profile (93). Among the cellular constituents 
of  the  skin,  it  was  exclusively  expressed  by  keratinocytes. 
The up-regulation of miR-203 in psoriatic plaques was con-
current  with  the  down-regulation  of  an  evolutionary  con-
served  target  of  miR-203,  SOCS-3,  which  is  involved  in  in-
flammatory responses and keratinocyte functions (93). These 
results  suggest  that  miRNA  deregulation  is  involved  in  the 
pathogenesis of psoriasis and contributes to the dysfunction 
of  the  cross  talk  between  resident  and  infiltrating  cells.  As 
mentioned, miRNAs were implicated in the pathogenesis of 
psoriasis and atopic eczema, the two most common chronic 
i n f l a m m a t o r y  d i s o r d e r s  i n  s k i n  ( 9 4 ) .  I n  p a r t i c u l a r ,  m i R - 2 0 3 ,  
the  first  skin-specific  miiRNA,  showing  an  intriguing  ex-
pression profile being confined to skin epithelium, is specifi-
cally  over-expressed  in  psoriasis  (94).  Interestingly,  the  au-
thors found that miR-146a, another miRNA showing specific 
up-regulation in psoriasis, is involved in the regulation of in-
nate  immune  responses  and  the  TNF-pathway  and  that 
miR-125b, another miRNA involved in TNF-pathway, is also MicroRNAs in Autoimmune and Psychoneurological Diseases
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deregulated in psoriasis and atopic eczema (94). As skin in-
flammation may serve as a model for chronic inflammatory 
disorders,  it  is  likely  that  miRNAs  involved  in  skin  in-
flammation will eventually emerge in other inflammatory or 
autoimmune disorders, and some of these may become dis-
e a s e  m a r k e r s  a n d  t h e r a p e u t i c  t a r g e t s  ( 9 4 ) .
    A recent study explored the association of miR-146a variant 
rs2910164  and  of  two  IRAK1  (target  of  miR146a)  poly-
morphisms  rs3027898  and  rs1059703  with  psoriasic  arthritis 
(83). Additionally, they observed strong statistical significant 
difference in IRAK1 rs3027898 polymorphism distribution be-
tween  patients  with  psoriasic  arthritis  and  controls  (33). 
Marginally significant difference was observed in distribution 
of  IRAK1  rs1059703  genotypes  between  patients  with  psor-
iasic  arthritis  and  controls,  but  no  difference  was  observed 
in miR-146a rs2920164 distribution (33). They noted that this 
is  the  first  study  that  addresses  IRAK1  rs3027898  poly-
morphisms association with susceptibility of psoriasic arthritis, 
but further studies could help to understand the extent of the 
proposed  association.
miRNAs IN INFLAMMATORY BOWEL DISEASE (IBD)
CD and UC are the 2 predominant types of idiopathic IBD 
that are distinguished by their underlying pathology (31,95). 
Despite pathological differences, both disease are thought to 
be T cell-driven disease and to result from a loss of immune 
t o l e r a n c e  i n  t h e  g u t  ( 3 1 ) .  T r e g  c e l l s  h a v e  a  c e n t r a l  r o l e  i n 
the maintenance of tolerance in the gut which is exemplified 
by the wasting disease and gastritis that develop in mice lack-
ing Treg cell (31). In a study conducted by Dalal and Kwon 
(61),  sigmoid  colon  biopsy  miRNA  microarray  profiles  for 
healthy control subjects and patients with active UC, inactive 
UC, chronic active CD, irritable bowel syndrome, and micro-
scopic colitis were compared. This comparison revealed that 
3  miRNAs  (miR-192,  miR-375,  and  miR-422b)  were  sig-
nificantly  decreased  in  the  UC  tissues,  while  8  miRNAs 
(miR-16,  miR-21,  miR-23a,  miR-24,  miR-29a,  miR-126,  miR- 
195, and let-7f) were significantly increased in active UC tis-
sues  (61).  And,  miR-192  and  miR-21  were  the  most  highly 
expressed of the active UC-associated miRNAs in human co-
lonic  tissues  (61).
    Wu et al. examined whether miRNAs are differentially ex-
pressed in UC tissues and are associated with expression of 
genes that regulate inflammation (96). They found that active 
UC  was  associated  with  the  differential  expression  of  11 
m i R N A S ;  3  w e r e  s i g n i f i c a n t l y  d e c r e a s e d  a n d  8  w e r e  s i g -
nificantly increased in UC tissues. In situ hybridization analy-
s i s  i n d i c a t e d  t h a t  m i R - 1 9 2 ,  a n  m i R N A  w i t h  d e c r e a s e d  e x -
pression in active UC, was predominantly localized to colonic 
epithelial  cells  (96).  They  also  found  that  macrophage  in-
flammatory  peptide  (MIP)-2  α,  a  chemokine  expressed  by 
epithelial  cells,  was  identified  as  a  target  of  miR-192  (96). 
Moreover,  they  reported  that  in  colon  epithelial  cells,  in-
duction of MIP-2α expression by TNF-α was accompanied 
by  a  concomitant  reduction  in  miR-192  expression  and 
miR-192 was observed to regulate the expression of MIP-2α 
(96). These findings expand the known roles of miRNAs, in-
dicating that tissues from patients with UC, and possibly other 
chronic  inflammatory  diseases,  have  altered  miRNA  expre-
ssion patterns. These finding also demonstrate that miRNAs 
regulate colonic epithelial cell-derived chemokine expression 
(96). Recently, Wu et al. investigated miRN A expression in 
CD patients (97). They performed miRNA microarray analysis 
followed by RT-PCR confirmation on sigmoid colon pinch bi-
opsies from 5 patients with chronically active CD and 13 con-
trol individuals. This comparison revealed that expression of 
miR-23b, miR-106, and miR-191 was increased in tissues from 
patients with active CD, while miR-19b and miR-629 were de-
creased in CD patients as compared to normal, healthy con-
trols (97). A study currently reported that 5 miRNAs were sig-
nificantly increased and 2 miRNAs (149* and miRplus-F1065) 
were  significantly  decreased  in  the  blood  of  active  CD  pa-
tients as compared to healthy controls (95). The authors also 
found  that  12  miRNAs  were  significantly  increased  and 
miRNA-505* was significantly decreased in the blood of active 
UC  patients  as  compared  to  healthy  controls  and  that  10 
miRNAs were significantly increased and one miRNA was sig-
nificantly  decreased  in  the  blood  of  active  UC  patients  as 
compared to active CD patients (95). They concluded that pe-
ripheral blood miRNAs can be used to distinguish active CD 
and UC from healthy controls (95). These data support the 
evidence that CD and UC are associated with different circu-
lating immune cell types and that the differential expression 
of peripheral blood miRNAs may form the basis of future di-
a g n o s t i c  t e s t s  f o r  I B D  ( 9 5 ) .  A n o t h e r  r e c e n t  s t u d y  d e m o n -
strated that in UC patients, 9 miRNAs (miR- 28-5p, miR-151-5p, 
miR-199a-5p,  miR-340,  miRplus-E1271,  miR-3180-3p,  miR-
plus-E1035,  miRplus-E1153,  and  miRplus-F1159)  were  in-
creased in the peripheral blood of patients with active UC, 
but not those with inactive UC (61). Among the 14 patients 
in the active CD group, miRNA expression did not differ sig-MicroRNAs in Autoimmune and Psychoneurological Diseases
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nificantly between the Crohn’s ileitis and Crohn’s colitis sub-
group (61). While UC and CD represent distinct disease with 
some overlap, identification of distinct miRNA expression pro-
files may provide an early method to determine a patients’s 
disease course (61). After the functional consequences of al-
t e r a t i o n s  i n  m i R N A  e x p r e s s i o n  a r e  e s t a b l i s h e d ,  m i R N A  m a y  
also  become  the  target  of  future  treatment.
miRNAs IN SKIN DISEASES 
Skin is the biggest organ in mammals and protect the body 
from  environmental  hazard  and  prevents  dehydration.  Em-
bryonic skin morphogenesis and homeostasis of adult skin re-
quire  an  accurately  controlled  gene  expression  in  spatio-
temporally  specific  manner  (32).  The  vascular  endothelial 
growth factor signaling path seem to be under repressor con-
trol by miRNAs (98). It is critically important to recognize that 
the understanding of cutaneous wound healing is incomplete 
without appreciating the functional significance of wound-in-
duced  miRNA  (98).  A  study  observed  that  the  cutaneous 
wound  healing  process  involved  changes  in  the  expression 
of specific miRNA at specific phases of wound healing (98). 
miRNAs  that  regulate  angiogenesis  include  miRNA-17-5p, 
cluster 17-92, miR-27a, miR-27b, miR-126, miR-130z, miR-210, 
miR-221, miR-222, miR-378, and the let7 family (99). Skin rep-
resents the largest organ in the human body, and its morpho-
genesis  has  been  shown  to  require  highly  coordinated  and 
undisrupted miRNA metabolism (99). Recent studies reported 
that miRNAs are involved in skin morphogenesis, hair follicle 
morphogenesis,  cutaneous  wound  healing,  skin  carcino-
genesis and autoimmune and chronic inflammatory diseases 
affecting  skin  such  as  SLE,  and  psoriasis  (62,63,100).
    Owing  to  its  highly  spatiotemporally  specific  expression 
pattern, miR-203 was the first miRNA investigated in the skin 
(32). As aforementioned, Sonkoly et al. examined miRNA ex-
pression  profile  in  the  skin  from  patients  with  psoriasis,  a 
common chronic inflammatory skin disease (93). The authors   
reported that miR-203 was significantly up-regulated in skin 
from patients with psoriasis and that miR-203 has 10 nucleo-
tides  with  complementarity  to  the  3'UTR  of  SOCS-3  mRNA 
(93). Decreased SOCS-3 protein expression, but not SOCS-3 
m R N A ,  w a s  a l s o  f o u n d  i n  p s o r i a s i s  s k i n  c o m p a r e d  w i t h  
healthy  skin,  suggesting  posttranscriptional  repression  of 
SOCS-3  (93,100).  Further  supporting  a  role  for  miR-203  in 
SOCS-3 regulation, a mutually exclusive expression pattern of 
miR-203 and SOCS-3 was observed in the skin from healthy 
subjects and patients with psoriasis (100). SOCS-3 was strong-
ly  expressed  by  the  basal  layer  of  keratinocytes  in  healthy 
skin, while it was suppressed in epidermis of psoriasis lesions 
(93).  These  data  suggest  that  down-regulation  of  miR-203 
may induce relief of posttranscriptional suppression of SOCS- 
3 expression in keratinocytes in patients with psoriasis. Since 
SOCS-3 is a negative regulator of IL-6 and IFN-γ-induced sig-
naling, up-regulation of SOCS-3 could result in constitutive ac-
tivation of STAT3, a downstream effector of the IL-6 and IFN-γ 
receptor  signaling  pathways  (100).  This  impaired  negative 
feedback  regulation  in  keratinocytes  may  consequently  con-
tributed  to  prolonged  skin  inflammation  (15,93).  These  data 
suggest that since miRNAS are master switches that ultimately 
affect complex cellular processes, and functions through the 
regulation of several proteins, miRNA- based therapies may 
be more effective than drugs targeting single proteins and that 
t h e  d i s e a s e - s p e c i f i c  m i R N A s  i d e n t i f i e d  i n  t h i s  s t u d y  c a n  b e  
used for potential therapeutic target in the treatment of chron-
ic  skin  inflammation  (15,93).
    Clues  for  the  functions  of  other  skin-expressed  miRNAs 
have  also  come  from  studies  of  their  function  in  human 
disease. miR-200 and miR-205 are both highly expressed in 
normal skin, and have been shown to specifically target the 
mRNA  of  the  transcriptional  repressor  of  E-Cadherin,  ZEB1 
a n d  Z E B 2  ( 3 2 ) .  T h e  s t u d y  h a v e  a l s o  s h o w n  t h a t  h i g h  e x -
pression of several miRNAs in the epidermis and hair follicle 
i s  n e c e s s a r y  f o r  n o r m a l  s k i n  d e v e l o p m e n t  ( 3 2 ) .  U s i n g  a  
mouse model of embryonic skin, progenitor cells were tar-
geted for Dicer knockout (63). The skin epithelium in Dicer 
knockout mice failed to produce mature miRNAs, and embry-
onic hair germs were found to evaginate into the epidermis 
rather than invaginate normally toward the dermis (63). Their   
further investigation also revealed a disturbance in the archi-
tecture of other epithelial tissues including the filiform papil-
lae of the tongue epithelium and rudimentary sweat glands 
of the plantar footpad epithelium (63). These results indicate 
that miRNA are also necessary for the morphogenesis of other 
stratified  epithelia  (32).  Interestingly,  a  more  recent  study 
showed that miR-155 is one of the highest-ranked up-regu-
lated  miRNAs  in  patients  with  atopic  dermatitis  and  in  the 
skin miR-155 was predominantly expressed in infiltrating im-
mune cells (101). This study also showed that miR-155 was 
up-regulated during  T-cell differentiation/activation and  was 
markedly induced by T-cell activators in PBMCs in vitro and 
by superantigen and allergens in the skin in vivo. Moreover,   
in  this  study,  CTLA-4,  an  important  negative  regulator  of MicroRNAs in Autoimmune and Psychoneurological Diseases
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T-cell activation, was identified as a direct target of miR-155 
(101). Over-expression of miR-155 in Th cells resulted in de-
creased  CTLA-4  levels  accompanied  by  an  increased  pro-
l i f e r a t i v e  r e s p o n s e  ( 1 0 1 ) .  T h e s e  d a t a  s t r o n g l y  s u g g e s t  t h a t  
miR-155 may contribute to chronic skin inflammation by in-
creasing  the  proliferative  response  of  Th  cells  through  the 
down-regulation of CTLA-4 (101). With the initial character-
ization of miRNA functions in mammalian skin, now we start 
to appreciate the significance of an accurately regulated pro-
t e i n  o u t p u t  n o t  o n l y  i n  n o r m a l  s k i n  d e v e l o p m e n t ,  b u t  a l s o 
in  human  skin  diseases  (32,63,101).
  Now, the stage is set to understand individual miRNA func-
tion and how critical biological events are controlled by this 
class of small RNA molecules. miRNAs are involved in regu-
lating epithelial anti-microbial defenses by targeting by epi-
thelial effector molecules and/or influencing intracellular sig-
naling pathway (100). Moreover, aberrant miRNA expression 
has  been  implicated  in  the  pathogenesis of  various disease 
at the skin and mucosa (32,63,101). Increasing understanding 
of  the  role  of  miRNA  in  epithelial  immunoregulation  and 
identification of miRNAs of pathogenetic significance will en-
hance  our  understanding  of  epithelial  immunobiology  and 
immunopathology  (100).
miRNAs IN PSYCHIATRIC AND NERUOLOGICAL 
DISORDERS AND MENTAL STRESS
Psychiatric illness are disabling disorders with poorly under-
stood underlying pathophysiologies. However, it is becoming 
increasingly evident that these illness results from disruption 
a c r o s s  w h o l e  c e l l u l a r  n e t w o r k s  r a t h e r  t h a n  a n y  p a r t i c u l a r  
monoamine system (66). Recent evidence continues to sup-
port the hypothesis that these illness such as schizophrenia, 
bipolar  disorders,  PD  and  major  depressive  disorders  arise 
from impairments in cellular plasticity cascades, which lead 
to aberrant information processing in the circuits that regulate 
mood,  cognition,  and  neurovegetative  functions,  such  as 
sleep, appetite, and energy (66). Psychiatric disorders are as-
sociated with a higher degree of comorbidity with other dis-
eases, such as cardiovascular disease, obesity, thyroid prob-
lems,  and  diabetes  (66).
    The  effects  of  miRNA-mediated  modulation  of  gene  ex-
pression during multiple steps of neuronal development, from 
early neurogenesis to synaptogenesis, have been well docu-
mented across the animal kingdom (65). As regards human 
miRNAs, it was estimated, based on high-throughput sequenc-
ing  data,  the  number  of  miRNAs  expressed  in  the  human 
brain may well exceed one-thousand (65,102). Interestingly, 
m a n y  m i R N A s  e x p r e s s e d  i n  t h e  h u m a n  b r a i n  a r e  n o t  c o n -
served beyond primates (34,65,102). Although functions have 
b e e n  a s s i g n e d  t o  o n l y  v e r y  f e w  b r a i n - s p e c i f i c  m i R N A s ,  i n -
creasing evidence suggests key roles in normal development, 
differentiation events, and homeostasis, as well as in related 
pathological conditions (34,65,102). A variety of miRNAs have 
been found in the CNS, and are believed to  play major phys-
iological roles in neuronal development (34,35,103). Neuro-
degenerative  diseases  results  from  dysfunction,  progressive 
d e t e r i o r a t i o n ,  a n d  e x t e n s i v e  l o s s  o f  n e u r o n s  i n  t h e  C N S  
and/or  peripheral  nervous  systems  (65,102).  Interestingly, 
miRNAs are altered by stress, glucocorticoides, mood stabil-
izer  in  a  particular  psychiatric  disorder  and  schizophrenia 
(66). Now, miRNAs are moving rapidly center stage as key 
regulators of neuronal development and function in addition 
to  important  contributions  to  neurodegenerative  disorder 
(34,35,104).
    Amyotrophic  lateral  sclerosis  (Lou  Gehrig’s  disease)  is  a 
neurodegenerative disease that specifically affects upper and 
lower motor neurons (MNs), leading to progressive paralysis 
and death (35). Similarly, juvenile forms of motor neuron dis-
eases  (MND)  are  related  to  posttranscriptional  regulators  of 
gene  expression  (35).  This  emerging  appreciation  of  RNA 
r e g u l a t o r y  f u n c t i o n  i n  n e u r o n s  s u g g e s t s  t h a t  m i R N A  i s  i n -
volved in the pathogenesis of MNDs. It has been shown that 
miRNA  dysfunction  causes  spinal  muscular  atrophy  (SMA) 
and that the heavy neurofilament subunit is a target of miR-9, 
a miRNA that is specifically down-regulated in a genetic mod-
el of SMA (35). These data provide evidence for miRNA func-
tion in spinal motor neuron disease and emphasize the poten-
tial role of miR-9-based regulatory mechanisms in adult neu-
rons  and  neurodegenerative  states  (35).
    A number of reports have emerged showing neurological 
disease-related perturbation of miRNAs (38,67,68). These al-
teration in miRNA expression may be a direct consequence 
of disease or may occur as a result of the loss of a specific 
cell population (38,67). Altered expression of miRNAs prior 
to the onset of or during the course of disease pathology rais-
es the possibility that expressing or inhibiting specific miRNAs 
might ameliorate the disease process and provide an effective 
treatment  (70,104,105).
    Importantly,  altered  expression  of  miRNA  has  been  ob-
served in PD (67,68), AD (36,38,102,106), HD (68), Toure-
tte’s  syndrome  (71),  DS  (70,72),  DiGeorge  syndrome  (70), MicroRNAs in Autoimmune and Psychoneurological Diseases
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Figure 3. Altered patterns of miRNA expression in brain parenchyma
and cerebrospinal fluid of patients with Alzheimer's disease.
prion disease (105) and Rett syndrome (70,71). Additionally, 
psychiatric  and  neurological  disorders,  including  schizo-
phrenia, depression and mental health disorders also appear 
to involve changes in miRNA expression (34,37,66,73,74,104).
  A s  r e g a r d s  A D ,  i n c r e a s i n g  e v i d e n c e  s u g g e s t s  r o l e  f o r  
miRNAs in the pathology of AD, particularly with respect to 
the regulation of β-amyloid precursor protein-converting en-
zyme 1 (BACE1). Among the AD-related miRNA expression 
changes, miR-107 was exceptional because miR-107 levels de-
creased significantly even in patients with the earliest stage 
of  pathology  (38).  Interestingly,  particular  cerebral  cortical 
laminas involved by AD pathology exhibit diminished neuro-
nal  miR-107  expression  (38).  Computational  analysis  pre-
dicted  that  the  3'UTR  of  BACE1  mRNA  is  targeted  multiply 
by miR-107 (38). Together, the study indicated that miR-107 
may be involved in accelerated disease progression through 
regulating  BACE1  (38).  Interestingly,  mutations  in  the  APP 
and  PSEN  genes  cause  Aβ accumulation  and  familial  AD 
(106,107).  Recently,  Hébert  et  al.  investigated  changes  in 
miRNA expression profiles of sporadic AD patients and found 
that several miRNAs potentially involved in the regulation of 
APP and BACE1 expression appeared to be decreased in dis-
eased brain (106). They also showed that miR-29a, miR-29b-1 
and miR-9 can regulate BACE1 expression  in vitro and that 
the miR-29a/b-1 cluster was significantly decreased in AD pa-
tients  displaying  abnormally  high  BACE1  protein  (106). 
Additionally, they provided evidence for a potential causal re-
l a t i o n s h i p  b e t w e e n  m i R - 2 9 a / b - 1  e x p r e s s i o n  a n d  A β gen-
eration in a cell culture model. They also proposed that loss 
of  specific  miRNAs  can  contribute  to  increased  BACE1  and 
Aβ levels in AD (106). These findings suggest a loss-of-func-
tion mechanisms contributing to sporadic AD and also pro-
vide an interesting molecular link between sporadic AD and 
the  amyloid  cascade.  In  different  studies  on  miRNA  ex-
pression profiling of AD-affected brain, the up-regulation of 
miR-125b  and  down-regulation  of  miR-9  and  miR-210  have 
been consistently reported (36). The up-regulation of miR-197 
and  down-regulation  of  miR-15,  miR-146b,  miR-181c  and 
miR-338 are commonly altered in AD brain parenchyma and 
cerebrospinal fluid, as shown in Fig. 3 (36). A recent study 
(67)  investigated  the  role  of  miRNAs  in  the  terminal  differ-
entiation, function, and survival of mammalian dopaminergic 
neurons (DNs). The authors identified miR-133b, that is spe-
cifically expressed in midbrain DNs and deficient in PD mid-
brain tissue that has lost midbrain DNs (67). Moreover, they 
also  reported  that  miR-133b  regulates  the  maturation  and 
function of midbrain DNs within a negative feedback circuit 
that includes the paired-like homeodomain transcription fac-
tor  Pitx3  (102).
    HD  is  an autosomal dominant neurodegenerative  disease 
caused by CAG trinucleotide repeat expansion in huntingtin, 
which encodes Huntingtin (Htt). Although Htt is ubiquitously 
expressed, patients with HD show predominantly CNS mani-
festations (68). Patients with HD experience abnormal motor 
movements,  cognitive  decline  and  psychiatric  disturbances 
that frequently result in premature death (68). One of the mo-
lecular  phenotype  in  HD  patients  is  transcriptional  mis-
regulation in striatum and distinct cortical regions (68). One 
putative mechanisms underlying the transcriptional changes is 
aberrant  cellular  distribution  of  the  transcriptional  repressor 
RE1-silencing TF (REST, also known as neuron restrictive si-
lencer  factor,  NRSF)  (68).  The  transcription  factor  REST  si-
lences neuronal gene expression in non-neuronal cells (68). 
In  neurons,  the  protein  is  sequestered  in  the  cytoplasm  in 
part through binding to Htt and polyglutamine expansions in 
Htt  which  caused  HD,  abrogates  REST-Htt  binding  (68). 
Packer et al. reported that levels of several miRNAs with up-
stream RE1 sites are decreased in HD patient cortices relative 
to healthy controls (68). Interestingly, one of these, the bi-
functional brain enriched miR-9/miR-9*, targets two compo-
nents of the REST complex: miR-9 targets REST and miR-9* 
targets CoREST (68). These data provided evidence for a dou-MicroRNAs in Autoimmune and Psychoneurological Diseases
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ble negative feedback loop between the REST silencing com-
plex  and  the  miRNAs  it  regulates  (68).
    DS or Trisomy 21, is the most common genetic cause of 
cognitive impairment and congenital heart defects in the hu-
man  population  (72).  Bioinformative  analysis  demonstrated 
that human chromosome 21 (Hsa21) harbors 5 miRNA genes; 
miR-99a, let-7c, miR-125b-2, miR-155, and miR-802 (72). Im-
p o r t a n t l y ,  m i R N A  e x p r e s s i n g  profiling,  miRNA  RT-PCR,  and 
miRNA  in situ hybridization  experiments  showed that these 
miRNAs are over-expressed in fetal brain and heart specimens 
f r o m  i n d i v i d u a l s  w i t h  D S  w h e n  c o m p a r e d  w i t h  a g e -  a n d  
sex-matched controls (72). The authors hypothesized that tri-
somic  21  gene  dosage  over-expression  of  Hsa21-derived 
miRNAs results in the decreased expression of specific target 
proteins and contribute, in part, to features of the neuronal 
a n d  c a r d i a c  D S  p h e n o t y p e  ( 7 2 ) .  T h e y  a l s o  n o t e d  t h a t  
Hsa21-derived miRNAs may provide novel therapeutic targets 
in the treatment of individuals with DS. Moreover, improved 
computational and experimental methods continue to reveal 
the location of new miRNAs, suggesting that there remain un-
identified miRNAs residing on chromosome 21, and in a DS 
critical region (DSCR), which could make excellent candidates 
to  study  the  molecular  pathogenesis  of  DS  further  (70).
    Schizophrenia is a severely debilitating psychiatric disorder 
characterized  by  a  diverse  range  of  symptoms.  While  ex-
tensive research has not determined the definitive cause(s), 
it is generally accepted that a number of influences including   
genetic, epigenetic, environmental and developmental factors 
are involved (32). Accumulating evidence showed numerous 
miRNAs associated with psychiatric disease (34,37,66,73,74). 
Perkins et al. hypothesized that schizophrenia might be asso-
ciated  with  altered  miRNA  profiles  (73).  To  investigate  this 
possibility,  they  compared  the  expression  of  264  human 
miRNAs from postmortem prefrontal cortex (Brodmann’s area 
9) tissue of individuals with schizophrenia or schizoaffective 
patients to tissue of 21 psychiatrically unaffected individuals 
(73).  Importantly,  they  identified  16  differentially  regulated 
miRNAs, 15 of which were down-regulated in schizophrenia. 
Of these, miR-26b, miR-30b, miR-29b, and miR-106b showed 
the greatest fold change, although all fold changes were less 
than 2-fold. Interestingly, for several of the differentially-ex-
pressed miRNAs, the ratio of mature miRNA to pri-miRNA was 
lower in schizophrenia, suggesting a disruption in miRNA bio-
genesis in schizophrenia (73). Burmistrova et al. reported that 
genetic association analysis of 300 schizophrenia and 316 nor-
mal control individuals revealed no statistically significant as-
sociation of any of the miR-130b allelic variants with schizo-
phrenia (108). Recently, however, Beveridge et al. observed 
miRNA dysregulaton and altered miRNA biogenesis in schizo-
phrenia brain tissue (37). Protein encoding genes have long 
been the major targets for research in schizophrenia genetics. 
However, with the identification of regulatory miRNAs as im-
portant  in  brain  development  and  function,  miRNA  genes 
have emerged as candidates for schizophrenia-associated ge-
netic factors (109). Hansen et al. found nominal association 
between brain-expressed miRNAs and schizophrenia for two 
SNPs  in  miRNAs  rs17578796  and  rs1700  located  in  has- 
miR-206 and hsa-miR-198  respectively  (109). More recently, 
Guo et al. have suggested that changes in gene expression 
may play an important role in etiology of schizophrenia, and 
that miRNAs and TFs are primary regulators of this gene ex-
p r e s s i o n  ( 1 1 0 ) .  T h i s  s t u d y  f o u n d  t h a t  a  T F  r e g u l a t e s  t r a n -
scription of its target gene by specifically binding to the TF 
binding  site  (TFBS)  in  the  gene's  promotor  region  (110). 
Since expression of miRNA　may be regulated by TF, TF and 
miRNA  reciprocally  regulate  one  another  to  form  feedback 
loops, or alternatively, both TF and miRNA may regulate their 
target  genes  and  form  feedforward  loops  (FFLs)  (110).
    Additionally, Guo et al. identified 32 FFLs among compiled 
schizophrenia-related miRNAs, TFs and schizophrenia candi-
date genes (SZGenes) and reported that these observed FFLs 
were  significantly  enriched  in  SZGenes  (110).  With  these 
findings, they also constructed a novel miRNA-TF regulatory 
network for schizophrenia (Fig. 4). Importantly, Beveridge et 
al.  reported  that  striking  deviation  in  global  miRNA  ex-
pression  was  observed  in  postmortem  tissue  from  both  the 
superior temporal gyrus (STG) and the dorsolateral prefrontal 
cortex (DLPFC) and seemed to involve an increase in miRNA 
biogenesis (74). The authors also observed schizophrenia-asso-
ciated up-regulation of a very large number of miRNAs (74): 
21% of expressed miRNAs in the STG and 9.5% of expressed 
miRNAs in the DLPFC. Additionally, they found that up-regu-
lated miRNAs were miR-181b, miR-219, and members of the 
miR-15 family. Surprisingly, of the 81 dysregulated miRNAs, 
only  4  were  up-regulated  in  both  the  STG  and  DLPFC 
(miR-128a,  miR-16,  miR-20a,  and  miR-338)  (74).  Together, 
their data suggest that schizophrenia is associated with a glob-
al increase in miRNA biogenesis and expression in the cere-
bral  cortex.  This  could  have  profound  neurodevelopmental 
and broader neurological implications in the cortext of schizo-
phrenia  by  influencing  genes  involved  in  cortical  structure 
and  neural  plasticity  (74).  A  more  complete  picture  of  the MicroRNAs in Autoimmune and Psychoneurological Diseases
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Figure 4. A overview of microRNA (miRNA)-transcription (TF) regul-
atory networks in schiziophrenia. A TF regulates transcription of its
target gene by specifically binding to the transcription factor binding 
site in gene's promotor region. TFs activate schizophrenia-related 
miRNAs (SZmiRNAs) and schizophrenia candidate genes (SZGenes). 
However, SZmiRNAs inhibit SZGenes and TFs. Both TF and miRNA 
regulate their target genes and form feedforward loops (FFLs). It was 
found that FFLS were significantly enriched in schizophrenia.　→
Activation;  ⇒ Inhibition. (See Text for details).
Figure 5. miRNAs influence the pathophysiology of psychiatric di-
sorders. A variety of miRNAs are found in the central nervous system
(CNS), and are believed to play critical roles in brain development and
structural plasticity. Modifiable changes in epigenetic or miRNA ex-
pression along with genetic polymorphisms activate or inhibit miRNA
in CNS and lead to either healthy or dysregulated mood. As regards 
therapeutic potential of miRNA in psychiatric diseases, targetting 
miRNAs may provide insight into the common and unique pathway.
Elucidating more miRNAs and predicted targets may reveal novel 
therapies that modified plasticity cascades to restore synaptic function, 
neuronal circuity, and mood regulation.
miRNAs that are dysregulated in psychiatric illness may im-
prove our understanding of the molecular mechanisms under-
lying  neuropsychiatric  phenotypes,  and  due  to  their  tuning 
effect on large numbers of protein, miRNAs may ultimately 
represent  a  new  therapeutic  target  for  psychiatric  disease 
(Fig.  5).
  Mammalian psychological stress is known to induce prom-
inent changes in neuronal activity and gene regulation across 
multiple brain region (111). Mental stress modifies both chol-
inergic neurotransmission and alternative splicing in the brain 
(111). Recently, Meerson et al. reported that stress changes 
brain miRNA expression and that some of these stress-regu-
lated miRNAs regulate alternative splicing (111). Interestingly, 
they  also  reported  that  acute  and  chronic  immobilization 
stress  differentially  altered  the  expression  of  numerous   
miRNAs in two stress-responsive regions of the rat brain, the 
h i p p o c a m p a l  C A 1  r e g i o n  a n d  t h e  c e n t r a l  n u c l e u s  o f  t h e   
amygdala and that miR-134 and miR-183 levels both increased 
in  the  amygdala  following  acute  stress,  compared  to  un-
stressed controls (111). Interestingly, moreover,  the authors 
showed that chronic stress decreased miR-134 levels, whereas 
miR-183 remained unchanged in both the amygdala and CA1 
(111).  They  also  found  that  miR-134  and  miR-183  share  a 
common predicted mRNA target, encoding the splicing factor 
SC35 (111). Importantly, chronic psychosocial stress is known 
to have adverse physiological effects that contribute to car-
diovascular disease, impaired immune function, inflammatory 
diseases, and impaired neuronal function and behavior (66). 
Glucocorticoids  are one  of the prominent mediators  of cel-
lular stress effect on neuronal function and behavior, and are 
known  to  structurally  alter brain  cytoarchitecture in  regions 
that  contribute  to  cognition,  memory,  and  emotion  (66). 
During the cellular stress response, miRNA have the capacity 
to change from translation suppressor to activators by forming MicroRNAs in Autoimmune and Psychoneurological Diseases
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new  interaction  between  miRNA/Argonaute  complexes  and 
RNA-binding  protein  that  alter  their  subcellular  localization 
(66). As described, accumulating evidence demonstrated that 
miRNAs are altered by stress, glucocorticoid, mood stabilizer 
(lithium and valproate) and in a particular psychic disorder, 
schizophrenia  (37,73,74).  Interestingly,  brief  exercise  alters 
miRNA  profile  in  circulating  neutrophils  in  humans  (112).
CONCLUSION
    MicroRNAs (miRNAs) are small noncoding RNA molecules 
that  negatively  regulate  gene  expression  via  degradation  or 
translational  repression  of  their  target  messenger  RNAs 
(mRNAs).  Recent  studies  have  clearly  demonstrated  that 
miRNAs are highly expressed in regulatory T (Treg) cells and 
a range of miRNAs are involved in the regulation of immunity 
and in the prevention of autoimmunity. It has been increas-
ingly  reported  that  miRNAs are  associated with various hu-
man diseases like autoimmune disease, skin disease, neuro-
logical  disease  and psychiatric  disease.  Recent studies have 
revealed that importance of miRNA regulation in safeguarding 
Treg cell function in the prevention of autoimmunity and au-
toimmune  diseases  like  rheumatoid  arthritis,  systemic  lupus 
erythematosus,  multiple  sclerosis,  psoriasis,  asthma,  in-
flammatory  bowel  disease  including  Crohn’s  disease,  ulcer-
ative colitis, and autoimmune diabetes. Although miRNA re-
search  in  the  field  of  dermatology  is  still  relatively  new, 
miRNAs have been the subject of much dermatological inter-
est  in  skin  morphogenesis  and  in  regulating  angiogenesis. 
Moreover, there is now compelling evidence that dysregula-
tion of miRNA networks is implicated in the development and 
onset of human neruodegenerative diseases, such as Alzheim-
er’s  disease,  Parkinson’s  disease,  Huntington’s  disease, 
Tourette’s syndrome, Down syndrome, depression and schi-
zophrenia.  In  this  review,  I  briefly  summarized  the  current 
studies about the roles of miRNAs in various autoimmune dis-
eases, skin diseases, psychoneurological disorders and mental 
stress. This review also explored the potential roles miRNAs 
can play in a variety of diseases, and suggested some possible 
therapeutic  application  for  restoring  or  inhibiting  miRNA 
function. The next  few years  should  see  many  studies  that 
further unravel the role of miRNAs and the molecular basis 
for their action in pathogenesis of diseases and immunity in 
addition to new efforts to harness this molecule for therapy.
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